Press Room

PhRMApedia Press Room

PhRMApedia's Press Room will provide the most recent press releases. Search PhRMApedia for additional press releases.  PhRMApedia is your new resource hub. You can search our entire database of media releases, reports, white papers, videos and more. Type your keywords in the search bar and explore PhRMA’s resources. Search results will appear by type, title and date.

Washington, DC (June 30, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced Brian Toohey will join the association as senior vice president for international advocacy. Toohey returns to PhRMA on July 11, 2016.

Read More

WASHINGTON  (June 10, 2016) — Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President, International, Jay Taylor,  issued the following statement on Colombia’s issuance of a Declaration of Public Interest:

 “We are very disappointed that Colombia has decided to issue a Declaration of Public Interest as a prelude to imposing additional price cuts on a proven cancer medicine.

Read More

Washington, D.C. (May 17, 2016) — The biopharmaceutical industry supported nearly 854,000 direct jobs and another 3.5 million jobs and more than $1.2 trillion in economic output in the United States in 2014, according to new research prepared for the Pharmaceutical Research and Manufacturers of America (PhRMA) by TEConomy Partners, LLC. The report, which analyzed state and national data across the large-scale biopharmaceutical sector supply chain, highlights how the discovery, development and delivery of innovative medicines translate into higher-wage jobs, increased tax revenue and greater economic output in our local communities

Read More

WASHINGTON (12 de mayo, 2016) – Las compañías miembros de la Empresa de Investigación y Fabricantes de Farmacéutica  de América (PhRMA) invirtieron aproximadamente $58,8 billones en investigación y desarrollo (I&D) en el año 2015, un aumento del 10,3 por ciento sobre el 2014.

Read More

WASHINGTON  (May 12, 2016) — Pharmaceutical Research and Manufacturers of America’s (PhRMA) member companies invested an estimated $58.8 billion in research and development (R&D) in 2015, up 10.3 percent from 2014. New R&D data based on findings from the 2016 PhRMA annual member survey released today in the 2016 Biopharmaceutical Research Industry Profile and corresponding industry chart pack, Biopharmaceuticals In Perspective, highlight the wide-reaching impact of PhRMA member companies on the economy and biopharmaceutical innovation.

Read More

WASHINGTON  (May 9, 2016) — America’s biopharmaceutical research companies are currently developing more than 560 medicines for patients with rare diseases, according to a report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA) and The ALS Association. Medicines in development include therapies for multiple myeloma, cystic fibrosis, amyotrophic lateral sclerosis (ALS) and enzyme deficiency disorders, providing treatment options for patients that had few or no treatment options before. 

Read More

Washington, DC (May 2, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced Lauren Levinson joined the organization as vice president of communications.

Levinson will help craft the association’s communications strategy and public positioning and will manage a team responsible for executive visibility, rapid response, proactive media outreach and a number of high-profile public affairs campaigns. She will report to Robert Zirkelbach, senior vice president of communications.

Read More

WASHINGTON, D.C. (April 27, 2016) – Pharmaceutical Research and Manufacturers of America (PhRMA) Vice President Jay Taylor issued the following statement today:

“PhRMA members appreciate the continuing work of the Office of the U.S. Trade Representative (USTR), the Departments of State and Commerce, U.S. overseas missions and others to establish and ensure full compliance with strong rules protecting patents and other intellectual property rights abroad. Special 301 is an essential tool to bring high-level attention to intellectual property and market access challenges in overseas markets that are harming American innovators, patients, and workers.

Read More

Washington, D.C. (April 25, 2016) — Pharmaceutical Research and Manufacturers of America (PhRMA) senior vice president Robert Zirkelbach today released the following statement in response to the Campaign for Sustainable Rx Pricing’s proposals: 

“These so-called market-based proposals are nothing more than a litany of new government regulations and mandates that would undermine the competitive market and empower government bureaucrats and insurance companies to make one-size-fits-all treatment decisions for patients. 

Read More

Washington, D.C. (April 7, 2016) Pharmaceutical Research and Manufacturers of America (PhRMA) issued the following statement on recommendations voted on at MedPAC’s April meeting:

“PhRMA strongly opposes the sweeping new Medicare Part D recommendations approved by MedPAC earlier today. Taken together, these recommendations will significantly harm beneficiaries by eroding coverage and protections for some of the most vulnerable enrollees in the program. MedPAC’s vote also ignores broad stakeholder concerns raised in response to these proposals.

Read More

Washington, D.C. (March 17, 2016) -- Pharmaceutical Research and Manufacturers of America (PhRMA) issued the following statement on the FDA and NIH Workforce Authorities Modernization Act:

“To fulfill its central mission of protecting public health by fostering timely patient access to safe and effective new medicines, the U.S. Food and Drug Administration (FDA) needs the ability to hire and retain sufficient numbers and types of technical and scientific experts to efficiently conduct reviews of human drug applications.

“While we are still reviewing the language in the Senate bill, we support enhanced hiring authority at the FDA as well as the National Institutes of Health (NIH).

Read More

Washington, D.C. (March 10, 2016) — Today, at the Pharmaceutical Research and Manufacturers of America (PhRMA) Board Meeting, new officers were elected to the board of directors. George A. Scangos, CEO, Biogen, was elected chairman of the PhRMA board. Joaquin Duato, worldwide chairman, pharmaceuticals, Johnson & Johnson was elected chairman-elect and Joseph Jimenez, CEO, Novartis AG assumed the role of board treasurer.

Scangos formerly held the position of chairman-elect and succeeds Kenneth C. Frazier chairman and CEO of Merck & Co., Inc. as PhRMA board chairman.

Read More

Washington, D.C. (March 10, 2016) — Today, at the Pharmaceutical Research and Manufacturers of America (PhRMA) 2016 Annual Meeting, PhRMA president and CEO Stephen J. Ubl announced the association’s policy solutions for delivering innovative treatments to patients.

“I am a passionate believer in the power of biomedical innovation to save and improve lives,” Ubl said. “We are on the cusp of a golden era in medical discovery and have the potential to revolutionize the treatment of costly and debilitating diseases. But we can’t take this progress for granted.

“Now is the time for PhRMA to play a leadership role in advancing pragmatic, pro-consumer policies that enhance the private market and address costs holistically.”

Read More

Washington, D.C. (March 10, 2016) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) honored 13 employees from 12 biopharmaceutical companies as “We Work For Health Champions” for their extraordinary efforts in policy advocacy and community service.

Established in 2009, the We Work for Health Champion Awards were created by the biopharmaceutical industry to honor employees who have not only excelled in their careers, but also shown an outstanding commitment to their communities through advocacy, community outreach, educational programs, community service and corporate education programs.

Read More

WASHINGTON, D.C. (March 8, 2016) – Today the Pharmaceutical Research and Manufacturers of America (PhRMA) spokesperson Allyson Funk provided the following statement in reaction to a newly released ASPE Issue Brief on Medicare Part B drugs and proposed Part B changes:

Read More

Pages

More On PhRMA — powered by PhRMApedia

Recommended

Cost in Context